 |
|
QMass® MR Enterprise Solution is a total workflow solution. Accessible when and where you need it and seamlessly integrated into your network. QMass MR Enterprise Solution is now an entire reviewing workstation by itself, with all the quantification tools you need. |
|
QMass MR
is considered the
industry-leading solution. It is used by
clinicians and research institutions worldwide,
and it has a proven track record in medical literature. |
| |
|
|
|
|
|
|
|
|
|
- Built-in connectivity platform
- Powerful cardiac MR reviewing: dedicated reviewing layouts, drag 'n' drop viewer, cross-referencing & synchronization
- T2* analysis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Saves time with its fast analyses and easy workflows
- Provides better insight through powerful reviewing capabilities
- Offers validated, reproducible results that you can rely on
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Integrated connectivity and reviewing platform, client/server solution
- Vendor-independent
- Automatic contour detection and image registration
- LV and RV function analysis
- Late-enhancement analysis1, with automatic transfer of contours
- First-pass perfusion analysis1 of rest and stress studies
- Comparison analysis of dobutamine stress studies
- T2* analysis
- Visual scoring of wall motion, scar transmurality and perfusion defects1
- Fast and powerful reporting
- Export formats
include PDF, HTML, XML, TXT, and DICOM
- Available with floating license mechanism, enabling efficient use of licenses
1QMass MR is cleared
for market in the US.
The first-pass perfusion analysis and late-enhancement
analysis modules of QMass MR have not received US 510(k) market
clearance as the use of contrast agents for cardiac MR procedures is
not FDA-approved. They are not available for sale in the United
States.
If you are located in the US and interested in these
modules for scientific research purposes only, please contact
us-sales@medis.nl.
|
|
|
